13FGuru
Sign in with Google Sign in with Discord

None · None

Alkermes plc ALKS

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.

Sources StockAnalysis company profile stockanalysis.com

Company profile

Business mix

  • The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
  • Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia.
  • The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products.
  • It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within drug manufacturers - specialty & generic?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 1 Current sample portfolio
Public mentions 0 Videos / interviews / letters

Current firm holders

Firm Weight Value Filing period
Baker Bros. Advisors 2.0% $354.0M 2026-03-31

Recent trading changes over the last 2 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 1 Last 2 13F filing periods
Net reducers 0 Last 2 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $67.9M Estimated from net added shares
Reduction amount $0 Estimated from net reduced shares
Net share change / base shares +23.7% +1,920,916 / 8,091,351
Baker Bros. Advisors 2 filing periods
13F 2025-12-31 Filed 2026-02-17
Major increase Shares 23.7% 13F value change +$37.4M
13F 2026-03-31 Filed 2026-05-15
Unchanged Shares 0.0% 13F value change $0
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 8,091,351 Last 2 periods +1,920,916 (+23.7%) Total shares 10,012,267 Value $354.0M

Recent mentions

No public mentions.